Aug. 22, 2019
UCalgary researchers find a way to stop lung damage from the body’s immune response
Discovery could help prevent deaths linked to sepsis and acute lung disease
University of Calgary researchers at the Cumming School of Medicine (CSM), led by Drs. Donna Senger, PhD, Paul Kubes, PhD, and Stephen Robbins, PhD, have discovered a new way to stop harmful inflammation in the lungs due to sepsis and injury.
“This work demonstrates the power of collaboration in solving complex health issues to benefit patients,” says Robbins, a professor in the departments of oncology, and biochemistry and molecular biology, and scientific director of the CIHR Institute of Cancer Research. “The research involved teams from 10 laboratories, nine at UCalgary, with investigators from the Arnie Charbonneau Cancer Institute and the Snyder Institute for Chronic Diseases.”
- Photo above: Donna Senger, left, and Stephen Robbins led a discovery that could help prevent death from sepsis. Photo by Kelly Johnston, Cumming School of Medicine
One in 18 deaths in Canada is connected to sepsis. It occurs when the body is fighting off severe infection. The immune system goes into overdrive, sending white blood cells to clear up the infection. The battle between your immune system and the infection leads to inflammation. A problem occurs when the white blood cells leave the bloodstream and move into the tissue to clean up the inflammation. In some cases, instead of cleaning up and moving on, they stay, and more white blood cells come in behind them. The accumulation causes damage to internal organs, like the lungs, and can lead to death.
Sepsis is not the only condition that leads to an unhealthy collection of white blood cells in the lungs. Inflammation caused by injury, and other diseases, can also create this harmful response. Acute lung injury is a leading cause of death in critical care in Canada.
Digging in to discover the underlying cause
The collaboration began about 15 years ago. It was a project based on a similar premise, with two distinct problems to solve. The researchers wanted to know what was causing some cells to bind in the lungs. Senger and Robbins are cancer biologists and were investigating how cancer metastasizes. They knew that some cancer cells target the lungs and somehow stay there and grow. Many people with cancerous tumours do not die from the primary tumour, but rather from where the cancer metastasizes. Meanwhile, Kubes, a specialist in inflammation, was investigating why white blood cells collect in the lungs. In conditions like sepsis, victims often die from the body’s response to the illness, not from sepsis itself.
Together they started screening for a molecule present in both processes. They targeted the lining of blood vessels in the lungs because they suspected a signal would be present that allows cancer cells and white blood cells to stop and collect there. That’s exactly where they found a molecule present during inflammation that could bind with white blood cells and help the cells pass from the bloodstream into the tissue. As long as those molecules are present, white blood cells continue to bind them.
Once the scientists understood how and why the white blood cells were entering the tissue, they went in search of an “off switch” to stop the molecule from binding with the white blood cell. The teams developed a drug-like molecule that when introduced into the blood stream prevents white blood cells from binding with the molecule.
“We discovered that by targeting this molecule we can stop the ill effects of sepsis, acute lung injury and death,” says Kubes, the director of the Snyder Institute for Chronic Diseases at the CSM and professor in the Department of Physiology and Pharmacology. “It could have an impact on any inflammatory condition in which lung injury is a contributor to worsening a patient’s condition.”
Translating the research from the laboratory to a treatment for patients
With this knowledge, the researchers have found a similar process that occurs in the liver. They’ve now patented two drug-like molecules that can prevent lung and liver damage due to inflammation. While all the research to date has been performed on mice, a phase I clinical trial is underway to begin human testing.
Kelly Johnston, Cumming School of Medicine
The researchers are also applying the findings to cancer metastasis in hopes this new understanding could lead to treatments to stop cancer cells from spreading in the body and targeting the liver and lungs.
“The molecule we discovered binds to both white blood cells and certain cancer cells,” says Senger, a research associate professor in the Department of Oncology. “We’ve developed a way to stop the white blood cells from binding and moving into the tissue. Now, we’re hoping to find a solution to prevent cancer cells from spreading to these organs.”
This work is supported by the Canadian Cancer Society, the Canadian Institutes of Health Research (CIHR), and the Dr. Robert C. Westbury Endowment for Melanoma Research.